“In the control arm, 7% of patients received “Traditional Chinese Medicine” as subsequent antitumor therapy, compared with only 0.6% in the ivonescimab arm.” — @dr_yakupergun on HARMONi-GI1
Ivonescimab investigational in the US @AkesoInc @SMMT_TX #ESMO26
https://hubs.ly/Q04Cfr7C0